Jessica Breton1, Arthur Kastl1, Natalie Hoffmann2, Rachel Rogers3, Andrew B Grossman1, Petar Mamula1, Judith R Kelsen1, Robert N Baldassano1, Lindsey Albenberg1. 1. Division of Gastroenterology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 2. Division of General Pediatrics, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 3. Biostatistics and Data Management Core, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Recent studies have shown that oral combination antibiotics may improve disease course in refractory inflammatory bowel disease (IBD). Here, we describe the use of combination oral antibiotics as salvage therapy in refractory ulcerative colitis (UC), Crohn's colitis, and IBD-unclassified (IBD-U) at a large pediatric IBD center. METHODS: Clinical response, disease activity indices, adverse events, and clinical outcomes were measured up to 1 year after antibiotic treatment in this retrospective cohort study of children with medically refractory IBD colitis. RESULTS: Sixty-three patients with refractory UC, Crohn's colitis, and IBD-U (median age [interquartile range {IQR}], 15.3 [11.2-16.5] years; median disease duration [IQR], 1.2 [0.41-4.6] years) received a combination of 3 or 4 oral antibiotics (most commonly amoxicillin, metronidazole, and either doxycycline or ciprofloxacin) for a median (IQR) of 29 (21-58) days. Thirty-four patients (54%) were deemed corticosteroid-refractory or -dependent, with the majority (62/63) having a previous or present loss of response or primary nonresponse to anti-tumor necrosis factor alpha (anti-TNFα) therapy. Use of combination antibiotics led to a significant decrease in median Pediatric Ulcerative Colitis Activity Index (PUCAI) score (IQR) from 55 (40-65) to 10 (0-40; P < 0.0001) over 3 ± 1 weeks, with 25/63 (39.7%) patients achieving clinical remission (PUCAI <10 points). The clinical benefits of oral antibiotics were independent of anti-TNFα therapy optimization. Among children entering clinical remission (n = 25), only 1 patient required surgery at 1-year follow-up, vs 10 patients in the nonresponder group. Negative predictors of response to combination antibiotics were exposure to doxycycline (odds ratio [OR], 0.25; 95% CI, 0.08-0.76) and PUCAI ≥65 at baseline (OR, 0.2; 95% CI, 0.05-0.74). CONCLUSIONS: Oral combination antibiotics appears to be an effective rescue and steroid-sparing therapy to induce remission in the short term in patients failing a biologic.
BACKGROUND: Recent studies have shown that oral combination antibiotics may improve disease course in refractory inflammatory bowel disease (IBD). Here, we describe the use of combination oral antibiotics as salvage therapy in refractory ulcerative colitis (UC), Crohn's colitis, and IBD-unclassified (IBD-U) at a large pediatric IBD center. METHODS: Clinical response, disease activity indices, adverse events, and clinical outcomes were measured up to 1 year after antibiotic treatment in this retrospective cohort study of children with medically refractory IBD colitis. RESULTS: Sixty-three patients with refractory UC, Crohn's colitis, and IBD-U (median age [interquartile range {IQR}], 15.3 [11.2-16.5] years; median disease duration [IQR], 1.2 [0.41-4.6] years) received a combination of 3 or 4 oral antibiotics (most commonly amoxicillin, metronidazole, and either doxycycline or ciprofloxacin) for a median (IQR) of 29 (21-58) days. Thirty-four patients (54%) were deemed corticosteroid-refractory or -dependent, with the majority (62/63) having a previous or present loss of response or primary nonresponse to anti-tumor necrosis factor alpha (anti-TNFα) therapy. Use of combination antibiotics led to a significant decrease in median Pediatric Ulcerative Colitis Activity Index (PUCAI) score (IQR) from 55 (40-65) to 10 (0-40; P < 0.0001) over 3 ± 1 weeks, with 25/63 (39.7%) patients achieving clinical remission (PUCAI <10 points). The clinical benefits of oral antibiotics were independent of anti-TNFα therapy optimization. Among children entering clinical remission (n = 25), only 1 patient required surgery at 1-year follow-up, vs 10 patients in the nonresponder group. Negative predictors of response to combination antibiotics were exposure to doxycycline (odds ratio [OR], 0.25; 95% CI, 0.08-0.76) and PUCAI ≥65 at baseline (OR, 0.2; 95% CI, 0.05-0.74). CONCLUSIONS: Oral combination antibiotics appears to be an effective rescue and steroid-sparing therapy to induce remission in the short term in patients failing a biologic.
Authors: Khurram J Khan; Thomas A Ullman; Alexander C Ford; Maria T Abreu; Amir Abadir; A Abadir; John K Marshall; Nicholas J Talley; Paul Moayyedi Journal: Am J Gastroenterol Date: 2011-03-15 Impact factor: 10.864
Authors: Alain Bitton; Donald Buie; Robert Enns; Brian G Feagan; Jennifer L Jones; John K Marshall; Scott Whittaker; Anne M Griffiths; Remo Panaccione Journal: Am J Gastroenterol Date: 2011-11-22 Impact factor: 10.864
Authors: William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: Dan Turner; Arie Levine; Johanna C Escher; Anne M Griffiths; Richard K Russell; Axel Dignass; Jorge Amil Dias; Jiri Bronsky; Christian P Braegger; Salvatore Cucchiara; Lissy de Ridder; Ulrika L Fagerberg; Séamus Hussey; Jean-Pierre Hugot; Sanja Kolacek; Kaija Leena Kolho; Paolo Lionetti; Anders Paerregaard; Alexander Potapov; Risto Rintala; Daniela E Serban; Annamaria Staiano; Brian Sweeny; Gigi Veerman; Gabor Veres; David C Wilson; Frank M Ruemmele Journal: J Pediatr Gastroenterol Nutr Date: 2012-09 Impact factor: 2.839
Authors: Dan Turner; Frank M Ruemmele; Esther Orlanski-Meyer; Anne M Griffiths; Javier Martin de Carpi; Jiri Bronsky; Gabor Veres; Marina Aloi; Caterina Strisciuglio; Christian P Braegger; Amit Assa; Claudio Romano; Séamus Hussey; Michael Stanton; Mikko Pakarinen; Lissy de Ridder; Konstantinos H Katsanos; Nick Croft; Víctor Manuel Navas-López; David C Wilson; Sally Lawrence; Richard K Russell Journal: J Pediatr Gastroenterol Nutr Date: 2018-08 Impact factor: 3.288
Authors: Ellie Chen; Hamzah Abu-Sbeih; Selvi Thirumurthi; Niharika Mallepally; Shruti Khurana; Dongguang Wei; Mehmet Altan; Van K Morris; Dongfeng Tan; Carlos H Barcenas; Yinghong Wang Journal: Ann Gastroenterol Date: 2019-11-21